SEC Comment Letter for TuHURA Biosciences, (HURA) — Jul 2, 2019
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: July 2, 2019 · CIK: 0001498382 · Accession: 0000000000-19-010688
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232332
Letter
July 2, 2019 Saiid Zarrabian President and Chief Executive Officer DelMar Pharmaceuticals, Inc. Suite 720-999 West Broadway Vancouver, British Columbia, Canada V5Z 1K5 Re:DelMar Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 25, 2019 File No. 333-232332 Dear Mr. Zarrabian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Steven M. Skolnick, Esq.
Show Raw Text
July 2, 2019
Saiid Zarrabian
President and Chief Executive Officer
DelMar Pharmaceuticals, Inc.
Suite 720-999 West Broadway
Vancouver, British Columbia, Canada V5Z 1K5
Re:DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed June 25, 2019
File No. 333-232332
Dear Mr. Zarrabian:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven M. Skolnick, Esq.